Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hugo Veyssiere"'
Autor:
Hugo Veyssiere, Margot Dressaire, Raphaël Pete, Céleste Pinard, Ioana Molnar, Catherine Abrial, Angeline Ginzac, Xavier Durando, Marielle Tekath
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-6 (2023)
Abstract Background Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women. Approximately 50% of breast cancers are discovered at an early stage in patients for whom conservative surgery is indicated. Int
Externí odkaz:
https://doaj.org/article/dbd159940b1e46f6adce6e7cfb9a7325
Autor:
Parvathy Venugopal, Hugo Veyssiere, Jean-Louis Couderc, Graziella Richard, Caroline Vachias, Vincent MIrouse
Publikováno v:
BMC Developmental Biology
BMC Developmental Biology, BioMed Central, 2020, 20 (1), ⟨10.1186/s12861-020-00218-0⟩
BMC Developmental Biology, Vol 20, Iss 1, Pp 1-12 (2020)
BMC Developmental Biology, 2020, 20 (1), ⟨10.1186/s12861-020-00218-0⟩
BMC Developmental Biology, BioMed Central, 2020, 20 (1), ⟨10.1186/s12861-020-00218-0⟩
BMC Developmental Biology, Vol 20, Iss 1, Pp 1-12 (2020)
BMC Developmental Biology, 2020, 20 (1), ⟨10.1186/s12861-020-00218-0⟩
Background : Scaffold proteins support a variety of key processes during animal development. Mutant mouse for the MAGUK protein Discs large 5 (Dlg5) presents a general growth impairment and moderate morphogenetic defects. Results : Here, we generated
Autor:
Hugo Veyssière, Sejdi Lusho, Ioana Molnar, Myriam Kossai, Maureen Bernadach, Catherine Abrial, Yannick Bidet, Nina Radosevic-Robin, Xavier Durando
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundTriple negative breast cancer (TNBC) accounts for 10-20% of breast cancers but has no specific therapy. While TNBC may be more sensitive to chemotherapy than other types of breast cancer, it has a poor prognosis. Most TNBC relapses occur du
Externí odkaz:
https://doaj.org/article/0c47419b39b64247a711d4de6f04cb08
Autor:
Hugo Veyssière, Judith Passildas, Angeline Ginzac, Sejdi Lusho, Yannick Bidet, Ioana Molnar, Maureen Bernadach, Mathias Cavaille, Nina Radosevic-Robin, Xavier Durando
Publikováno v:
F1000Research, Vol 9 (2021)
Introduction: Patient-derived xenografts (PDX) can be used to explore tumour pathophysiology and could be useful to better understand therapeutic response in breast cancer. PDX from mammary tumours are usually made from metastatic tumours. Thus, PDX
Externí odkaz:
https://doaj.org/article/02d754ecdaf34879a66a07e365073f48